From left to right:
Samuel Levy, PhD
Scientific Advisor, NexGen Sequencing
Samuel Levy, PhD, received a B.Sc. in Molecular Biophysics at the University of Leeds, UK, and in 1986 was awarded the PhD, in cell and computational biology at the University of Bristol, UK. He was in receipt of a NATO/SERC postdoctoral fellowship for a two-year period studying structural and biochemical changes in plant cell walls at the École Normale Supérieure, France. More…
Richard Scuderi, MD, PhD
Medical Director
Dr. Richard Scuderi currently serves as a member of Pacific Rim Pathology group with a specialty in Hematopathology. He is certified by the American Board of Pathology and by the Medical Board of California. Dr. Scuderi has authored numerous of pertinent papers on various hematology-oncology topics including Hodgkin and non-Hodgkin lymphoma, hemoglobinopathies, and acute lymphoblastic leukemia. More…
Patrick O’Connor, PhD
Scientific Advisor
Dr. O’Connor is a leader in the field of oncology drug discovery and development. His contributions include over 100 publications and patents, and over 20 compounds brought into development (e.g., Axitinib (VEGF, PII/PIII), AG14699/PF-01367338 (PARP, PII/III), Crizotinib (C-Met/ALK, PII/III)), RDEA119/BAY869766 (MEK, Phase I/II). Prior to joining the industry, Dr. O’Connor spent 10 years at the National Cancer Institute in Bethesda, Maryland. More…
Art Mendoza, MD
Medical Advisor
Dr. Mendoza is the Chief of Pathology and a Medical Director at Sharp Memorial Hospital, San Diego, and a Director of Pathology at Mary Birch Hospital for Women, Sharp Healthcare. He was formerly the Medical Director for the Hematology/Coagulation Lab at Sharp Memorial Hospital, and for the Molecular Pathology Lab at Sharp Pathology Labs. More…
Kenna Anderes, PhD
Scientific Advisor
Kenna Anderes is an advisor to Molecular Response with 20 years research and development experience in cancer, cardiovascular & metabolic disease. Dr. Anderes has demonstrated leadership and the ability to formulate the strategic direction of large and small multidisciplinary teams by leveraging target validation, mechanism of action, biomarker and co-diagnostic tools to ensure scientific validation preclinically in order to position programs for clinical proof of concept. More…